Law, WJohnson, CRushton, MDent, S2019-05-012019-05-0120171198-0052https://doi.org/10.20381/ruor-23377http://hdl.handle.net/10393/39129Patients with breast cancer (bca) who overexpress her2 (the human epidermal growth factor receptor 2) are at risk for cardiotoxicity when treated with anthracycline-based chemotherapy and her2-targeted agents. The Framingham risk score (frs) is a validated tool that stratifies patients into high-, intermediate-, or low-risk groups and calculates their 10-year risk of developing cardiovascular disease (cvd) based on past medical history, systolic blood pressure, and measurement of serum lipids. We retrospectively analyzed patients with her2-positive bca to determine whether the frs predicts adverse cardiovascular (CV) events or cardiotoxicity in patients treated using anthracyclines or her2-targeted therapy, or both.enCardio-oncologyFramingham risk scorebreast cancercardiotoxicityher2trastuzumabArticle10.3747/co.24.3684